Harvard University brought together researchers studying Marijuana’s health impacts with policymakers who are working to implement new laws in ways that will benefit and protect public health.
Video courtesy of the Harvard University YouTube channel
Click on this link to visit the National Cancer Institute website.
The following is from the National Cancer Institute webpage linked to above titled “Cannabis and Cannabinoids (PDQ®)–Patient Version
Questions and Answers About Cannabis”
Have any preclinical (laboratory or animal) studies been conducted using Cannabis or cannabinoids?
Preclinical studies of cannabinoids have investigated the following:
Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells.
A laboratory study of cannabidiol (CBD) in estrogen receptor positive and estrogen receptor negative breast cancer cells showed that it caused cancer cell death while having little effect on normal breast cells. Studies in mouse models of metastatic breast cancer showed that cannabinoids may lessen the growth, number, and spread of tumors.
A review of 34 studies of cannabinoids in glioma tumor models found that all but one study showed that cannabinoids can kill cancer cells without harming normal cells.
A laboratory study of cannabidiol (CBD) in human glioma cells showed that when given along with chemotherapy, CBD may make chemotherapy more effective and increase cancer cell death without harming normal cells. Studies in mouse models of cancer showed that CBD together with delta-9-THC may make chemotherapy such as temozolomide more effective.
Something which has apparently been known in Cancer Research circles, has been formally announced to the public.
“Cannabis has been shown to kill cancer cells in the laboratory” posted by the National Cancer Institue at cancer.gov
Photo courtesy of the United States Fish and Wildlife Service
The info below is from the website of the National Cancer Institute (https://www.cancer.gov)
Cannabis and Cannabinoids (PDQ®)–Patient Version
- Questions and Answers About Cannabis
- Current Clinical Trials
- About This PDQ Summary
- General CAM Information
- Evaluation of CAM Therapies
- Questions to Ask Your Health Care Provider About CAM
- To Learn More About CAM
- View All Sections
- Cannabis , also known as marijuana, is a plant grown in many parts of the world which produces a resin containing compounds called cannabinoids. Some cannabinoids are psychoactive (acting on the brain and changing mood or consciousness) (see Question 1).
- The use of Cannabis for medicinal purposes dates back to ancient times (see Question 3).
- By federal law, the possession of Cannabis is illegal in the United States outside of approved research settings. However, a growing number of states, territories, and the District of Columbia have enacted laws to legalize medical marijuana (see Question 1).
- In the United States, Cannabis is a controlled substance requiring special licensing for its use (see Question 1 and Question 3).
- Cannabinoids are active chemicals in Cannabis that cause drug -like effects throughout the body, including the central nervous system and the immune system (see Question 2).
- The main active cannabinoid in Cannabis is delta-9-THC. Another active cannabinoid is cannabidiol (CBD), which may relieve pain, lower inflammation, and decrease anxiety without causing the “high” of delta-9-THC (see Question 2).
- Cannabinoids can be taken by mouth, inhaled, or sprayed under the tongue (see Question 5).
- Cannabis and cannabinoids have been studied in the laboratory and the clinic for relief of pain, nausea and vomiting, anxiety, and loss of appetite (see Question 6 and Question 7).
- Cannabis and cannabinoids may have benefits in treating the symptoms of cancer or the side effects of cancer therapies. There is growing interest in treating children for symptoms such as nausea with Cannabis and cannabinoids, although studies are limited (see Question 7).
- Two cannabinoids (dronabinol and nabilone) are drugs approved by the U.S. Food and Drug Administration (FDA) for the prevention or treatment of chemotherapy -related nausea and vomiting (see Question 7 and Question 10).
- Cannabis has been shown to kill cancer cells in the laboratory (see Question 6).
- At this time, there is not enough evidence to recommend that patients inhale or ingest Cannabis as a treatment for cancer-related symptoms or side effects of cancer therapy (see Question 7).
- Cannabis is not approved by the FDA for use as a cancer treatment (see Question 9).
******* end of post from cancer.gov *******
The following are additional links with info related to Cannabis and THC being able to kill Cancer Cells:
Antineoplastic Activity of Cannabinoids
Cannabinoid Receptor Ligands Mediate Growth Inhibition & Cell Death In Mantle Cell Lymphoma
Δ9-Tetrahydrocannabinol Induces Apoptosis in Human Prostate PC-3 Cells via a Receptor-Independent Mechanism
Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma
Cannabinoid Receptors As Novel Targets for the Treatment of Melanoma
Photo of Cannabis plants courtesy of A7nubis and commons.wikimedia.org
Note from Vince: This is am extremely important change as the Cannabis grown by NIDA is an uncommon variety and apparently low in THC. The FDA could approve a Medical Study of the use of high THC Cannabis in the treatment of Cancer, but NIDA always had the final word. If they approved a medical study (their usual common response was “No”) the study had to use the NIDA supplied Cannabis variety.
WASHINGTON, D.C. — Today, the Drug Enforcement Administration (DEA) announced their intention to grant licenses to additional marijuana growers for research, thereby ending the DEA-imposed 48-year monopoly on federally legal marijuana. Since 1968, the University of Mississippi, under contract to the National Institute on Drug Abuse (NIDA), has maintained the only facility in the United States with federal permission to grow marijuana for research.
“It’s a complete and total end of the NIDA monopoly! There has been no production monopoly on any other Schedule I substance, like MDMA or LSD—only the cannabis plant. Licensing non-government cannabis producers, and thereby creating a path to FDA approval, will finally facilitate the removal of marijuana from Schedule I, and ultimately allow patients to receive insurance coverage for medical marijuana,” said Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS).
MAPS has been working to eliminate this cannabis research blockade since 1999. NIDA’s marijuana is eligible for research, but cannot be sold as a prescription medicine, making it unacceptable to the Food and Drug Administration (FDA) for use in future Phase 3 studies. Ending the monopoly finally allows for a pathway to FDA approval for marijuana, which would thereby trigger rescheduling.
In 2001, MAPS partnered with University of Massachusetts-Amherst Professor Lyle Craker, Ph.D., to apply for a DEA license and end the monopoly. In 2007, after years of bureaucratic delays and lengthy legal hearings, a DEA Administrative Law Judge (ALJ) recommended that it would be in the public’s interest to grant Craker the license. In 2009, after almost two more years of delays and less than a week before the inauguration of President Obama, former DEA Administrator Michelle Leonhart rejected the ALJ recommendation. In 2011, Craker sued the DEA in the U.S. First Circuit Court of Appeals. In its 2013 decision, the Court uncritically accepted the DEA’s arguments that NIDA’s monopoly provided “an adequate supply produced under adequately competitive conditions.”
Since the 2013 decision, Craker’s argument that NIDA does not have an adequate supply has become significantly more apparent. NIDA has been unable to provide the strains requested for MAPS’ long-delayed Phase 2 clinical trial of smoked marijuana to treat symptoms of posttraumatic stress disorder (PTSD) in 76 U.S. veterans. As a result, the study is proceeding with lower potency marijuana than what MAPS researchers requested.
The DEA has previously claimed that U.S. international treaty obligations under the United Nations Single Convention on Narcotic Drugs (Single Convention) require a federal monopoly, but in April 2016, the State Department released a statement clarifying that the Single Convention does not in fact limit the number of U.S. marijuana producers.
Furthermore, the DEA’s 2009 rejection of the ALJ recommendation to license Craker relied heavily on a U.S. Department of Health and Human Services (HHS) protocol review process, which was eliminated in 2015.
MAPS’ upcoming Phase 2 clinical trial of marijuana for PTSD in veterans is in collaboration with investigators in Phoenix, Arizona, and at Johns Hopkins University, the University of Colorado, and the University of Pennsylvania. The study is funded by a $2.15 million grant to MAPS from the State of Colorado. The study has received full regulatory approval, and will be the first randomized controlled trial of whole plant marijuana as a treatment for PTSD.
Founded in 1986, MAPS is a non-profit research and educational organization working to evaluate the safety and efficacy of botanical marijuana as a potential prescription medicine for specific medical uses approved by the FDA.
- Official Statement from DEA
- 2007 DEA Administrative Law Judge Findings
- 2013 First Circuit Court Decision
- 2015 HHS Statement Ending PHS Protocol Review
- Legal analysis to be submitted in support of Craker’s new application
Additional information can be found at maps.org/research/mmj/dea-license.
Rick Doblin, Ph.D., MAPS Executive Director
Natalie Ginsberg, MAPS Policy & Advocacy Manager
Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
This TEDx Talk is titled “Making Peace with Cannabis“. It features Zach Walsh, PhD, who is an Assistant Professor in the UBC Department of Psychology and Co-Director for the Centre for the Advancement of Psychological Science and Law. He is also involved in a current study at UBC which is investigating treating PTSD using Medical Cannabis.
Video is courtesy of the TEDx Talks YouTube channel
The Parents “were putting Cannabinoid Oil on the baby’s pacifier twice a day, increasing the dose… And within two months there was a dramatic reduction”.
“Dr. Courtney pointed out that the success of the Cannabis approach means that “this child, because of that, is not going to have the long-term side effects that would come from a very high dose of chemotherapy or radiation“”.
Video is courtesy of the Lincoln Horsley YouTube channel
Posted by Vincent Banial
The above link is from our new blog called Uniquely Cannabis. It’s the first post, with more to come.
Main focus of Uniquely Cannabis will be Medical Cannabis / Marijuana. The reason for creating it was that I had read that Cannabis could help those suffering from different Cancers including Leukemia.
I hope that the site will become an infobase about Medical Cannabis / Marijuana to help inform people. I had watched someone take their final breath, because they had Leukemia and nothing helped. Wish that I had known about Cannabis Oil. It might have helped. If it did, then life would have been vastly different.
Posted by Vincent Banial
Medical Cannabis could possibly halt Alzheimer’s and could maybe even reverse the damage caused by Alzheimer’s. That is my interpretation of the results from a medical study conducted by Salk Institute Scientists.
The following is from their News Release:
“Salk Institute scientists have found preliminary evidence that tetrahydrocannabinol (THC) and other compounds found in marijuana can promote the cellular removal of amyloid beta, a toxic protein associated with Alzheimer’s disease.”
“Although other studies have offered evidence that cannabinoids might be neuroprotective against the symptoms of Alzheimer’s, we believe our study is the first to demonstrate that cannabinoids affect both inflammation and amyloid beta accumulation in nerve cells,” says Salk Professor David Schubert, the senior author of the paper.”
I am not giving any medical Advice with the following statements. Maybe discuss with the Medical Doctor taking care of a family member suffering from Alzheimer’s. Ask the Doctor for a prescription for Medical Cannabis, which is available in Canada and many states in America. Working with their Medical Doctor, one could maybe create your own private human trial under your Doctor’s supervision. In my mind, the risk is extremely low. Keep notes and search the internet for Cogniition Tests (Alzheimer’s Associations are a good resource) . Under the care of a Medical Doctor, testing to see if Medical Cannabis could reduce the effects of Alzheimer’s and improve cognition, in my opinion, has a high safety factor. For example, no one has died from smoking or eating too much Cannabis. On the other hand, thousands of people have died due to major Liver damage caused by overdosing on medication such as Tylenol.
Click on the following link to read the News Release about the new finding from the Salk Institute website.
Click on this link to visit the Journal Aging and Mechanisms of Disease to read the published Salk Institute Study titled : “Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids“
|Title:||Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids|
|Author:||Antonio Currais, Oswald Quehenberger, Aaron M Armando, Daniel Daugherty, Pam Maher et al.|
|Publication:||npj Aging and Mechanisms of Disease|
|Publisher:||Nature Publishing Group|
|Date:||Jun 23, 2016|
|Copyright © 2016, Rights Managed by Nature Publishing Group|
Click on this link to download a PDF copy of the study from the site of the Journal